Chinese PE firm Yunfeng Capital and Hong Kong-listed medical device manufacturer MicroPort Scientific Corporation will acquire US-listed LivaNova's cardiac rhythm management (CRM) business for $190 million in cash.
Taiwan Liposome, a venture capital-backed manufacturer of pain medication and treatments for eye conditions, has filed for a NASDAQ IPO.
China’s Harbin Pharmaceutical Group, which is controlled by CITIC Capital, has agreed to acquire a 40% stake in GNC Holdings for $300 million, becoming the largest shareholder in the US-based nutritional supplements retailer.
Sistema Asia Fund, a VC unit of Russian conglomerate Sistema, has led a $12 million Series B funding round for Indian fitness lifestyle app operator HealthifyMe.
Sino-US healthcare specialist Vivo Capital has led a $55 million round of funding for Beijing Innocare, a biopharmaceutical company that develops treatments for cancer and autoimmune diseases.
Allergan, a US-listed pharmaceutical company and the owner of Botox cosmetic injectable products, has agreed to acquire Elastagen, an Australian skin treatment developer backed by a number of VCs, in a deal worth up to $260 million.
Sailing Capital has invested $30.6 million in Cellular Biomedicine Group (CBMG), a China and US-based biopharmaceutical company focused on immunotherapy cancer treatments.
Pacific Equity Partners (PEP) has agreed to buy listed Australian medical devices manufacturer LifeHealthcare for an enterprise valuation of approximately A$211 million ($166 million).
Ping An Insurance Group has raised $2.2 billion in private equity funding for its three technology businesses: Ping An Good Doctor, Ping An Healthcare Management, and OneConnect Financial Technology.
A group of VCs led by China’s 6 Dimensions Capital and Sino-US investor Danhua Capital (DHVC) has committed $10 million to US and Singapore-based Engine Biosciences.
Permira's first Australia investment provides EQT Partners with an exit from medical imaging service I-Med Radiology Network
Ping An Healthcare & Technology - the PE-backed business that runs the healthcare-focused mobile app known as Ping An Good Doctor in China - is seeking a separate listing in Hong Kong from its parent company Ping An Insurance.
Permira is set to make its first investment in Australia after reaching an agreement with EQT Partners to acquire I-Med Radiology Network.
Healthcare-focused private equity firm Quadria Capital has made an investment of undisclosed size in Malaysian diagnostics services company Lablink.
Crescent Capital Partners has acquired Australia-based clinical research organization (CRO) Nucleus Network from The Baker Institute, an independent research institute that focuses on heart disease and diabetes.
Partners Group has sold its entire 21% stake in Australia’s Victorian Comprehensive Cancer Centre (VCCC) to AMP Capital.
CITIC Capital has increased its stake in Harbin Pharmaceutical Group to 60.86%, becoming the controlling shareholder of the Chinese state-backed business in which it has been an investor since 2005.
Morgan Stanley Private Equity Asia (MSPEA) has completed two investments in India, committing INR1.6 billion ($25.1 million) to medical devices business Sahajanand Medical Technologies (SMT) and INR1.52 billion to health foods producer Southern Health...
CDH Investments has invested in Huiyi Huiying (HY), a Beijing-based start-up that offers artificial intelligence-based (AI) medical imaging diagnosis. Financial terms were not disclosed.
Advantech Capital and SDIC Fund Management have led a $76 million Series A round for Chinese biotechnology company KBP Biosciences.
A group of investors including SBCVC and Kexin Capital have backed a $32 million funding round for China’s HaploX Biotechnology.
A technology-focused fund managed by Apax Partners has led a $60 million Series D round of funding for SoYoung, a Chinese online marketplace specializing in cosmetic surgery.
Innovation Network Corporation of Japan (INCJ) has joined a JPY3.7 billion ($33 million) Series C funding round for Megakaryon, a domestic medical research company.
OrbiMed has invested a further $7.5 million in the active pharmaceutical ingredient (API) unit of India-listed drug maker Vivimed Labs.